HOOKIPA Pharma (HOOK)

Executive Summary

HOOKIPA Pharma is a clinical-stage biopharmaceutical company pioneering immunotherapies based on its proprietary arenavirus vector platform. The technology is designed to induce robust and durable T cell and antibody responses against infectious diseases and cancers. The company's lead programs target HPV16+ cancers (HB-201/HB-202), KRAS-mutated solid tumors (HB-300), and infectious diseases including cytomegalovirus (HB-101) and HIV. HOOKIPA's approach aims to reprogram the immune system to recognize and attack disease cells more effectively, potentially offering new treatment options for patients with high unmet needs. In 2026, HOOKIPA is poised for several value-inflecting milestones. The company plans to report Phase 2 data for HB-201 in HPV16+ head and neck cancer, which could validate its platform in oncology. Additionally, IND clearance and trial initiation for HB-300 targeting KRAS mutations is anticipated. These catalysts, along with progress in its infectious disease programs, underscore HOOKIPA's potential to advance novel immunotherapies. However, clinical-stage biotech companies carry inherent risks, including trial outcomes and regulatory hurdles. The company's financial position and partnership dynamics will be key to watch.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data for HB-201 in HPV16+ head and neck cancer30% success
• Q3 2026FDA IND clearance for HB-300 (KRAS-mutated cancers) Phase 1/2 trial60% success
• TBDUpdate on CMV vaccine (HB-101) Phase 2 data or partnership40% success